In reply
- PMID: 24536028
- PMCID: PMC3958465
- DOI: 10.1634/theoncologist.2013-0395
In reply
Abstract
Merseburger, Bellmunt, Jenkins et al. respond to Dr. Luzzatto’s letter regarding the use of the term “castration resistant” in describing the progression of prostate cancer.
Comment on
-
Perspectives on treatment of metastatic castration-resistant prostate cancer.Oncologist. 2013;18(5):558-67. doi: 10.1634/theoncologist.2012-0478. Epub 2013 May 13. Oncologist. 2013. PMID: 23671006 Free PMC article. Review.
-
Resistance to "castration-resistant".Oncologist. 2014 Mar;19(3):305. doi: 10.1634/theoncologist.2013-0363. Epub 2014 Feb 17. Oncologist. 2014. PMID: 24536029 Free PMC article.
References
-
- Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res. 2004;64:9209–9216. - PubMed
-
- Heidenreich A, Bastian PJ, Bellmunt J, et al. European Association of Urology. Prostate Cancer Guidelines. 2013. Available at http://www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf. Accessed October 2013.
-
- Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. J Urol. 2013;190:429–438. - PubMed
-
- Horwich A, Parker C, de Reijke T, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 [Epub ahead of print] - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources